Existing medicines for antibody-related kidney transplant rejection
Computational Drug Repositioning for Antibody Mediated Renal Allograft Rejection
This project looks for already-approved drugs or drug combinations that could calm harmful antibodies that attack kidney transplants.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11321234 on NIH RePORTER |
What this research studies
Researchers will analyze gene activity patterns from kidney transplant biopsies that show antibody-mediated rejection and from stable transplants. They will use computer tools and public drug-gene databases to find approved drugs that reverse the harmful molecular patterns. Promising single drugs and drug combinations will be tested in human cells and in biopsy tissue outside the body to study how they work. Successful leads would be advanced toward further testing in transplant patients.
Who could benefit from this research
Good fit: Patients with biopsy-confirmed antibody-mediated rejection after a kidney transplant would be the most relevant candidates for potential future testing or to provide samples.
Not a fit: People without antibody-mediated rejection (for example, those with other causes of transplant dysfunction) or those unable to undergo biopsy-based sampling are unlikely to benefit directly from this project.
Why it matters
Potential benefit: If successful, this work could identify existing drugs that slow or stop antibody-mediated rejection, offering quicker treatment options for transplant patients.
How similar studies have performed: Drug-repurposing methods have produced candidate treatments in other conditions and the investigators' preliminary analyses already point to leads for antibody-mediated rejection, but clinical benefit remains unproven.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Sarwal, Minnie M — University of California, San Francisco
- Study coordinator: Sarwal, Minnie M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.